- Trials with a EudraCT protocol (899)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
899 result(s) found for: Chemotherapy agent.
Displaying page 4 of 45.
EudraCT Number: 2015-003741-26 | Sponsor Protocol Number: GS-US-350-1604 | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate... | |||||||||||||
Medical condition: Metastatic castrate-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003540-21 | Sponsor Protocol Number: CPKC412E2301 | Start Date*: 2018-05-23 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412... | ||
Medical condition: newly diagnosed FLT3 non-mutated acute myeloid leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) BE (Completed) IT (Completed) PT (Completed) FR (Completed) NO (Completed) ES (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002054-55 | Sponsor Protocol Number: PXD101-301-G | Start Date*: 2006-01-12 |
Sponsor Name:Topotarget A/S | ||
Full Title: A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma | ||
Medical condition: Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003907-20 | Sponsor Protocol Number: C16051 | Start Date*: 2019-07-10 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit | ||||||||||||||||||
Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract... | ||||||||||||||||||
Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002354-12 | Sponsor Protocol Number: CMBG453X2101 | Start Date*: 2016-02-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000654-23 | Sponsor Protocol Number: EORTC 18032 | Start Date*: 2004-12-09 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group | |||||||||||||
Medical condition: Stage IV Metastatic Melanoma: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001747-29 | Sponsor Protocol Number: OSI-774-302 | Start Date*: 2006-11-21 | |||||||||||
Sponsor Name:OSI Pharmaceuticals, LLC | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Pati... | |||||||||||||
Medical condition: Stage IB-IIIA Non-small Cell Lung Carcinoma with EGFR-positive tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) DE (Prematurely Ended) AT (Completed) CZ (Prematurely Ended) FR (Completed) GR (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001947-28 | Sponsor Protocol Number: T2017-002 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:Therapeutic Advances in Childhood Leukemia Consortium (TACL) | ||||||||||||||||||
Full Title: A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | ||||||||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LLy) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007849-13 | Sponsor Protocol Number: GCIG/JGOG 3017 | Start Date*: 2009-03-27 | |||||||||||
Sponsor Name:Kitasato institute clinical trial coordinating center | |||||||||||||
Full Title: Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary | |||||||||||||
Medical condition: Clear Cell Carcinoma of the Ovary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006507-36 | Sponsor Protocol Number: AVF3693g | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METAST... | |||||||||||||
Medical condition: Previously Treated Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) BE (Completed) FR (Completed) CZ (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2011-003168-63 | Sponsor Protocol Number: AMLSG16-10/CPKC412ADE02T | Start Date*: 2012-04-27 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leuk... | ||
Medical condition: Patients with confirmed diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003896-35 | Sponsor Protocol Number: EORTC 26041_22041 | Start Date*: 2005-08-01 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM | |||||||||||||
Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Completed) GB (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002992-25 | Sponsor Protocol Number: 20140346 | Start Date*: 2019-09-13 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of... | ||||||||||||||||||
Medical condition: gastrointestinal or colorectal adenocarcinoma, which includes cancers of the esophagus, stomach, colon, or rectum. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Trial now transitioned) HU (Prematurely Ended) PT (Trial now transitioned) AT (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004844-43 | Sponsor Protocol Number: MK-0517-045 | Start Date*: 2019-10-07 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CIN... | |||||||||||||
Medical condition: Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) PL (Completed) HU (Completed) NL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002566-50 | Sponsor Protocol Number: 8951-CL-0103 | Start Date*: 2018-10-02 | |||||||||||||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||||||||||||
Full Title: A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whos... | |||||||||||||||||||||||
Medical condition: Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000524-82 | Sponsor Protocol Number: RMH CCR No 3107 | Start Date*: 2008-10-09 | |||||||||||
Sponsor Name:Royal Marsden Hospital | |||||||||||||
Full Title: MESH: A Non-Randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer with MSH2 Deficiency | |||||||||||||
Medical condition: Metastatic colorectal cancer resistanct to standard chemotherapy with evidence of deficiency of the mismatch repair gene MSH2, either on immunohistochemistry of tumour histology or on testing of pe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001356-37 | Sponsor Protocol Number: NSGO-CC-0304 | Start Date*: 2004-09-10 |
Sponsor Name:Nordic Society for Gynecological Cancer | ||
Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer | ||
Medical condition: Metastatic or recurrent cervical cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005395-34 | Sponsor Protocol Number: CTC-cDDP | Start Date*: 2013-04-25 |
Sponsor Name:Erasmus MC | ||
Full Title: Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients | ||
Medical condition: Metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003618-15 | Sponsor Protocol Number: IRFMN-GBM-6272 | Start Date*: 2013-09-17 |
Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri" | ||
Full Title: Multicenter, randomized, non-comparative, open-label phase II trial on the efficacy of Ortataxel and Fotemustine in recurrent glioblastoma | ||
Medical condition: Glioblastoma in recurrence/progression after surgery (or biopsy), radiotherapy and chemotherapy with temozolomide | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002721-37 | Sponsor Protocol Number: CLBH589BDE03T | Start Date*: 2009-06-09 |
Sponsor Name:Medizinische Fakultät der TU-München, vertreten durch den Dekan | ||
Full Title: An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T | ||
Medical condition: A study with patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases (HDACs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
